MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2023.09.049

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2023

Clinical and Dosimetric Results of Proton or Photon Radiation Therapy for Large (>5 cm) Hepatocellular Carcinoma: A Retrospective Analysis.

Hsieh Rodney Cheng-En, Lee Ching-Hsin, Huang Hsiao-Chieh, Wu Shu-Wei, Chou Chen-Yu, Hung Sheng-Ping, Lee Chao-Wei, Krishnan Sunil, Venkatesulu Bhanu Prasad, Lee Jin-Chiao, Chou Yung-Chih, Chan Kun-Ming, Lin Po-Ting, Lee Wei-Chen, Lin Chen-Chun, Lin Shen-Yen, Hong Ji-Hong

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Our purpose was to report the clinical and dosimetric attributes of patients with large unresectable hepatocellular carcinoma (HCC) undergoing proton or photon radiation therapy.

METHODS AND MATERIALS: We retrospectively analyzed the outcomes and dosimetric indices of 159 patients with >5 cm nonmetastatic HCC who underwent definitive radiation therapy using either protons (N = 105) or photons (N = 54) between 2014 and 2018. Additional photon plans were performed in the 105 proton-treated patients using the same dose prescription criteria for intragroup dosimetric comparison.

RESULTS

After a median follow-up of 47 months, patients with biologically effective dose (BED10) ≥ 75 Gy exhibited significantly better local control (LC; 2-year: 85.6% vs 20.5%; P < .001), progression-free survival (PFS; median, 7.4 vs 3.2 months; P < .001), and overall survival (OS; median, 18.1 vs 7.3 months; P < .001) compared with those with BED10 < 75 Gy. Notably, proton-treated patients had a significantly higher BED10 (96 vs 67 Gy; P < .001) and improved LC (2-year: 88.5% vs 33.8%; P < .001), PFS (median, 7.4 vs 3.3 months; P = .001), and OS (median, 18.9 vs 8.3 months; P < .001) than those undergoing photon radiation therapy. Furthermore, patients treated with protons had significantly lower V1 of the liver (P < .001), mean upper gastrointestinal tract dose (P < .001), and mean splenic dose (P < .001), with significantly decreased incidences of radiation-induced liver disease (P = .007), grade ≥3 upper gastrointestinal bleeding (P = .001), and grade ≥3 lymphopenia (P = .003). On multivariate analysis, proton radiation therapy consistently correlated with superior LC (P < .001), PFS (P < .001), and OS (P < .001). In intragroup dosimetric comparison, photon plans demonstrated significantly higher mean liver dose (P < .001) compared with actually delivered proton treatments, and 72 (69%) of them had mean liver dose exceeding 28 Gy, which necessitated target dose de-escalation.

CONCLUSIONS

In the context of large HCC radiation therapy, a higher target BED10 was associated with improved outcomes. Notably, proton therapy has demonstrated the capability to deliver ablative doses while also being accompanied by fewer instances of severe toxicity.

Для цитирования: Hsieh Rodney Cheng-En, Lee Ching-Hsin, Huang Hsiao-Chieh, Wu Shu-Wei, Chou Chen-Yu, Hung Sheng-Ping, Lee Chao-Wei, Krishnan Sunil, Venkatesulu Bhanu Prasad, Lee Jin-Chiao, Chou Yung-Chih, Chan Kun-Ming, Lin Po-Ting, Lee Wei-Chen, Lin Chen-Chun, Lin Shen-Yen, Hong Ji-Hong. Clinical and Dosimetric Results of Proton or Photon Radiation Therapy for Large (>5 cm) Hepatocellular Carcinoma: A Retrospective Analysis.. International journal of radiation oncology, biology, physics. 2023. DOI: 10.1016/j.ijrobp.2023.09.049.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.